Fondaparinux and rivaroxaban have higher efficacy of reducing venous thromboembolism after total hip or knee arthroplasty, but also an increased risk of major bleeding.
Cardiology care in patients with newly diagnosed atrial fibrillation was associated with reductions in stroke and death.
Idarucizumab can effectively reverse the anticoagulant effect of dabigatran.
Bristol-Myers Squibb is recalling one lot of Eliquis after finding that 1 of the bottles contained the wrong dosage.
A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.
Anticoagulation treatment for patients with mechanical heart valves during pregnancy is linked to maternal and fetal risks.
A new model can help predict acute gastrointestinal bleeding, associated with increased risk of all-cause mortality.
Treating patients with at least a 17.5% predicted one-year venous thromboembolism risk may cost-effective.
Fewer adverse events were linked to electronic-health-based management of oral anticoagulation therapy.
The delayed start of anticoagulation treatment for atrial fibrillation has been linked to an increase risk for dementia.
Direct oral anticoagulation reduced the risk of congestive heart failure admissions and all-cause mortality in both genders.
Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&AMarch 23, 2017
Incidence of major bleeding events was lower with dabigatran vs warfarin in atrial fibrillation ablation.
Results from the EINSTEIN CHOICE trial plus an interview with investigator Philip Stephen Wells, MD, FRCP(C), MSc.
According to research, many patients with afib who were later diagnosed with acute ischemic stroke may not have been receiving appropriate anticoagulation therapy.
Regardless of intracerebral hemorrhage location, restarting oral anticoagulation is associated with favorable outcomes.
Of the 80% of patients prescribed oral anticoagulants, nearly 50% were prescribed non-vitamin K antagonist anticoagulants.
Periprocedural Anticoagulation in Atrial Fibrillation: American College of Cardiology Decision PathwayFebruary 06, 2017
The American College of Cardiology released a decision pathway for managing periprocedural anticoagulation in patients with nonvalvular atrial fibrillation
Compared with warfarin, inpatient costs for newly diagnosed atrial fibrillation were lower for dabigatran and rivaroxaban.
Almost half of the patients were not prescribed an oral anticoagulant despite a median CHA2DS2VASc score of 5.
Continuing wafarin after a diagnosis of dementia appears to have a protective effect in prevention of ischemic stroke, major bleeding, and all-cause mortality.
Patients who received proton pump inhibitor co-therapy when beginning warfarin had a 24% decreased risk for upper gastrointestinal bleeding.
In patients with an event-free period of at least 12 months after atrial fibrillation ablation, risk of stroke or recurrent atrial fibrillation is low.
About 1 in 8 patients in the ORBIT-AF II registry were given "off-label" non-vitamin K antagonist doses.
Obstructive sleep apnea is an independent risk factor for recurrent pulmonary embolism in patients who stop taking oral anticoagulation for a first episode.
Relative to tricyclic antidepressants, SSRIs were associated with an increased risk for intracranial hemorrhage.
Patients with a CHA2DS2-VASc score of 2 or more who discontinued warfarin had higher rates of stroke than those who continued treatment.
Cardiac-related death is the main cause of mortality among patients with atrial fibrillation on anticoagulants.
Venous thromboembolism occurred in 1.4% of the treatment group and 1.8% of the control group.
Patients taking dabigatran after their bleeding event were nearly half as likely to have another major bleeding event within 1 year compared to those who took warfarin.
Pre-ablation trans-esophageal echocardiography rates dropped from 86% to 42%; meanwhile, cerebrovascular accidents occurred in only 0.40% of patients.
The Cardiology Advisor Articles
- Beta-Blockers Reduce CV Mortality in Heart Failure With Preserved Ejection Fraction
- Timing of BP Measurements in Orthostatic Hypotension Linked to Adverse Effects
- Hypertension, Diabetes in Midlife Increase Risk of Dementia
- Reduced GFR Associated With Increased Atrial Fibrillation Risk
- Spironolactone Oral Suspension Formulation Approved by FDA
- Assessing Chest Pain in ER With Short-term Risk Stratification Tool
- Cardiac Rehabilitation: Changes, Challenges, and Clinician Perspectives
- Shortness of Breath and Palpitations After a Funeral: Depression or Something Worse?
- Newly Diagnosed Atrial Fibrillation Benefits From Cardiology Care vs Primary Care
- Noncalcified, High-Risk Coronary Plaque Burden Increased With Psoriasis
- Case Study: Cardiac Manifestations of Rheumatoid Arthritis
- Preventing Venous Thromboembolism After Hip, Knee Arthoplasty: Comparing Anticoagulant Efficacy
- Patients Report Breakdowns in Hospital Care
- Evolocumab Added to Statin Therapy Does Not Affect Cognition
- Risk Stratification Using Platelet Aggregation in Stable CAD